Pfizer And Taisho Reach Deal for Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.
You may also be interested in...
Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?